Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio

Proactive

Tue, March 31, 2026 astatine 10:26 AM CDT 1 min read

Eli Lilly and Co $LLY said connected Tuesday it volition get Centessa Pharmaceuticals $CNTA for $38 per stock successful cash, with a imaginable contingent worth close (CVR) worthy up to $9 per share, valuing the woody astatine astir $6.3 cardinal upfront and up to $7.8 cardinal including milestones.

The acquisition adds Centessa’s sleep-wake upset pipeline, including its pb plus cleminorexton, to Lilly’s neuroscience business.

Cleminorexton is being evaluated successful objective trials for narcolepsy benignant 1, narcolepsy benignant 2, and idiopathic hypersomnia.

Centessa shares surged astir 45% successful aboriginal trading connected Tuesday, portion Lilly shares roseate astir 2.9%.

BMO Capital reiterated an Outperform standing and a $1,300 terms people connected Eli Lilly shares pursuing the acquisition announcement. The steadfast said the woody is affirmative for Lilly, noting the institution is acquiring from a presumption of spot and diversifying its concern up of immoderate large nonaccomplishment of exclusivity events.

The woody highlights Lilly’s effort to broaden its portfolio beyond metabolic treatments and fortify its beingness successful neuroscience.